27252647|t|In Alzheimer's Disease, 6-Month Treatment with GLP-1 Analog Prevents Decline of Brain Glucose Metabolism: Randomized, Placebo-Controlled, Double-Blind Clinical Trial.
27252647|a|In animal models, the incretin hormone GLP-1 affects Alzheimer's disease (AD). We hypothesized that treatment with GLP-1 or an analog of GLP-1 would prevent accumulation of Abeta and raise, or prevent decline of, glucose metabolism (CMRglc) in AD. In this 26-week trial, we randomized 38 patients with AD to treatment with the GLP-1 analog liraglutide (n = 18), or placebo (n = 20). We measured Abeta load in brain with tracer [(11)C]PIB (PIB), CMRglc with [(18)F]FDG (FDG), and cognition with the WMS-IV scale (ClinicalTrials.gov NCT01469351). The PIB binding increased significantly in temporal lobe in placebo and treatment patients (both P = 0.04), and in occipital lobe in treatment patients (P = 0.04). Regional and global increases of PIB retention did not differ between the groups (P >= 0.38). In placebo treated patients CMRglc declined in all regions, significantly so by the following means in precuneus (P = 0.009, 3.2 mumol/hg/min, 95% CI: 5.45; 0.92), and in parietal (P = 0.04, 2.1 mumol/hg/min, 95% CI: 4.21; 0.081), temporal (P = 0.046, 1.54 mumol/hg/min, 95% CI: 3.05; 0.030), and occipital (P = 0.009, 2.10 mumol/hg/min, 95% CI: 3.61; 0.59) lobes, and in cerebellum (P = 0.04, 1.54 mumol/hg/min, 95% CI: 3.01; 0.064). In contrast, the GLP-1 analog treatment caused a numerical but insignificant increase of CMRglc after 6 months. Cognitive scores did not change. We conclude that the GLP-1 analog treatment prevented the decline of CMRglc that signifies cognitive impairment, synaptic dysfunction, and disease evolution. We draw no firm conclusions from the Abeta load or cognition measures, for which the study was underpowered. 
27252647	3	22	Alzheimer's Disease	Disease	MESH:D000544
27252647	47	52	GLP-1	Gene	2740
27252647	86	93	Glucose	Chemical	MESH:D005947
27252647	206	211	GLP-1	Gene	2740
27252647	220	239	Alzheimer's disease	Disease	MESH:D000544
27252647	241	243	AD	Disease	MESH:D000544
27252647	282	287	GLP-1	Gene	2740
27252647	304	309	GLP-1	Gene	2740
27252647	340	345	Abeta	Gene	351
27252647	380	387	glucose	Chemical	MESH:D005947
27252647	411	413	AD	Disease	MESH:D000544
27252647	455	463	patients	Species	9606
27252647	469	471	AD	Disease	MESH:D000544
27252647	494	499	GLP-1	Gene	2740
27252647	562	567	Abeta	Gene	351
27252647	595	604	(11)C]PIB	Chemical	MESH:C475519
27252647	606	609	PIB	Chemical	MESH:C069442
27252647	625	634	(18)F]FDG	Chemical	MESH:D019788
27252647	636	639	FDG	Chemical	MESH:D019788
27252647	716	719	PIB	Chemical	MESH:C069442
27252647	794	802	patients	Species	9606
27252647	855	863	patients	Species	9606
27252647	909	912	PIB	Chemical	MESH:C069442
27252647	989	997	patients	Species	9606
27252647	1422	1427	GLP-1	Gene	2740
27252647	1571	1576	GLP-1	Gene	2740
27252647	1641	1661	cognitive impairment	Disease	MESH:D003072
27252647	1663	1683	synaptic dysfunction	Disease	MESH:C536122
27252647	1745	1750	Abeta	Gene	351
27252647	Association	MESH:D000544	2740
27252647	Negative_Correlation	2740	351
27252647	Association	MESH:C069442	MESH:C536122
27252647	Association	MESH:D005947	MESH:D000544
27252647	Association	MESH:C069442	351
27252647	Association	MESH:C475519	351
27252647	Association	MESH:D005947	2740
27252647	Association	MESH:C069442	MESH:D000544

